UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.16 Million Stock Position in Novavax, Inc. (NASDAQ:NVAX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 19.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 268,684 shares of the biopharmaceutical company's stock after purchasing an additional 44,359 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.17% of Novavax worth $2,160,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Deutsche Bank AG raised its stake in Novavax by 47.5% during the 4th quarter. Deutsche Bank AG now owns 123,581 shares of the biopharmaceutical company's stock valued at $994,000 after purchasing an additional 39,787 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Novavax by 10.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 101,812 shares of the biopharmaceutical company's stock valued at $817,000 after buying an additional 9,711 shares during the period. Arizona State Retirement System increased its holdings in Novavax by 14.9% in the 4th quarter. Arizona State Retirement System now owns 41,793 shares of the biopharmaceutical company's stock valued at $336,000 after buying an additional 5,407 shares during the period. Bank of New York Mellon Corp increased its holdings in Novavax by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company's stock valued at $3,509,000 after buying an additional 1,664 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Novavax by 28.8% in the 4th quarter. JPMorgan Chase & Co. now owns 76,576 shares of the biopharmaceutical company's stock valued at $616,000 after buying an additional 17,101 shares during the period. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Price Performance

Shares of NVAX traded up $0.46 during trading hours on Friday, hitting $7.45. The stock had a trading volume of 7,414,868 shares, compared to its average volume of 6,764,981. The company's fifty day moving average is $6.61 and its two-hundred day moving average is $7.76. Novavax, Inc. has a 52 week low of $5.01 and a 52 week high of $19.50. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -3.30, a P/E/G ratio of 2.85 and a beta of 2.80.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share for the quarter, topping the consensus estimate of $0.71 by $2.22. The firm had revenue of $666.66 million during the quarter, compared to the consensus estimate of $204.08 million. During the same period in the previous year, the company posted ($1.05) EPS. The firm's revenue for the quarter was up 610.3% compared to the same quarter last year. Equities analysts predict that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. TD Cowen raised shares of Novavax to a "hold" rating in a report on Thursday, February 27th. BTIG Research assumed coverage on shares of Novavax in a report on Friday, February 28th. They issued a "buy" rating and a $19.00 price target on the stock. B. Riley reissued a "buy" rating on shares of Novavax in a report on Monday, May 19th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $19.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.